Challenges and Priorities in the Management of HIV/HBV and HIV/HCV Coinfection in Resource-Limited Settings

被引:43
作者
Easterbrook, Philippa [1 ]
Sands, Anita [2 ]
Harmanci, Hande [3 ]
机构
[1] WHO, Dept HIV AIDS, Treatment & Care, CH-1211 Geneva 27, Switzerland
[2] WHO, Dept Essential Med & Hlth Prod, CH-1211 Geneva 27, Switzerland
[3] WHO, Global Hepatitis Programme, CH-1211 Geneva 27, Switzerland
关键词
HIV-hepatitis B coinfection; HIV-hepatitis C coinfection; resource-limited settings; HEPATITIS-C-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; LIVER FIBROSIS PROGRESSION; CHRONIC VIRAL-HEPATITIS; B-VIRUS; GLOBAL EPIDEMIOLOGY; INFECTED PATIENTS; HIV-INFECTION; NONINVASIVE MARKERS; BLOOD-DONORS;
D O I
10.1055/s-0032-1316476
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Liver disease due to chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection is now emerging as an increasing cause of morbidity and mortality in human immunodeficiency virus- (HIV-) infected persons in resource-limited settings (RLS). Existing management guidelines have generally focused on care in tertiary level facilities in developed countries. Less than half of low-income countries have guidance, and in those that do, there are important omissions or disparities in recommendations. There are multiple challenges to delivery of effective hepatitis care in RLS, but the most important remains the limited access to antiviral drugs and diagnostic tests. In 2010, the World Health Assembly adopted a resolution calling for a comprehensive approach for the prevention, control, and management of viral hepatitis. We describe activities at the World Health Organization (WHO) in three key areas: the establishment of a global hepatitis Program and interim strategy; steps toward the development of global guidance on management of coinfection for RLS; and the WHO prequalification program of HBV and HCV diagnostic assays. We highlight key research gaps and the importance of applying the lessons learned from the public health scale-up of ART to hepatitis care.
引用
收藏
页码:147 / 157
页数:11
相关论文
共 68 条
  • [1] The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana
    Allain, JP
    Candotti, D
    Soldan, K
    Sarkodie, F
    Phelps, B
    Giachetti, C
    Shyamala, V
    Yeboah, F
    Anokwa, M
    Owusu-Ofori, S
    Opare-Sem, O
    [J]. BLOOD, 2003, 101 (06) : 2419 - 2425
  • [2] Epidemiology of viral hepatitis and HIV co-infection
    Alter, MJ
    [J]. JOURNAL OF HEPATOLOGY, 2006, 44 : S6 - S9
  • [3] [Anonymous], 2012, DIAGN LAB TECHN
  • [4] [Anonymous], 2010, VIR HEP WHA63 18 63
  • [5] [Anonymous], ANT THER HIV INF AD
  • [6] Ansa V O, 2002, East Afr Med J, V79, P254
  • [7] Non-Invasive markers for hepatic fibrosis
    Baranova, Ancha
    Lal, Priyanka
    Birerdinc, Aybike
    Younossi, Zobair M.
    [J]. BMC GASTROENTEROLOGY, 2011, 11
  • [8] Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients
    Benhamou, Y
    Bochet, M
    Thibault, V
    Di Martino, V
    Caumes, E
    Bricaire, F
    Opolon, P
    Katlama, C
    Poynard, T
    [J]. HEPATOLOGY, 1999, 30 (05) : 1302 - 1306
  • [9] Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
    Benhamou, Y
    Bochet, M
    Di Martino, V
    Charlotte, F
    Azria, F
    Coutellier, A
    Vidaud, M
    Bricaire, F
    Opolon, P
    Katlama, C
    Poynard, T
    [J]. HEPATOLOGY, 1999, 30 (04) : 1054 - 1058
  • [10] Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine
    Bessesen, M
    Ives, D
    Condreay, L
    Lawrence, S
    Sherman, KE
    [J]. CLINICAL INFECTIOUS DISEASES, 1999, 28 (05) : 1032 - 1035